Investigation of parent-of-origin effects induced by fenofibrate treatment on triglycerides levels
- PMID: 30255771
- PMCID: PMC6156838
- DOI: 10.1186/s12863-018-0640-9
Investigation of parent-of-origin effects induced by fenofibrate treatment on triglycerides levels
Abstract
Background: Genome-wide association studies performed on triglycerides (TGs) have not accounted for epigenetic mechanisms that may partially explain trait heritability.
Results: Parent-of-origin (POO) effect association analyses using an agnostic approach or a candidate approach were performed for pretreatment TG levels, posttreatment TG levels, and pre- and posttreatment TG-level differences in the real GAW20 family data set. We detected 22 genetic variants with suggestive POO effects with at least 1 phenotype (P ≤ 10- 5). We evaluated the association of these 22 significant genetic variants showing POO effects with close DNA methylation probes associated with TGs. A total of 18 DNA methylation probes located in the vicinity of the 22 SNPs were associated with at least 1 phenotype and 6 SNP-probe pairs were associated with DNA methylation probes at the nominal level of P < 0.05, among which 1 pair presented evidence of POO effect. Our analyses identified a paternal effect of SNP rs301621 on the difference between pre- and posttreatment TG levels (P = 1.2 × 10- 5). This same SNP showed evidence for a maternal effect on methylation levels of a nearby probe (cg10206250; P = 0.01). Using a causal inference test we established that the observed POO effect of rs301621 was not mediated by DNA methylation at cg10206250.
Conclusions: We performed POO effect association analyses of SNPs with TGs, as well as association analyses of SNPs with DNA methylation probes. These analyses, which were followed by a causal inference test, established that the paternal effect at the SNP rs301621 is induced by treatment and is not mediated by methylation level at cg10206250.
Keywords: DNA methylation; Epigenetics; Fenofibrate treatment; Parent-of-origin effects; Triglycerides.
Conflict of interest statement
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Similar articles
-
Modification effect of fenofibrate therapy, a longitudinal epigenomic-wide methylation study of triglycerides levels in the GOLDN study.BMC Genet. 2018 Sep 17;19(Suppl 1):75. doi: 10.1186/s12863-018-0643-6. BMC Genet. 2018. PMID: 30255776 Free PMC article.
-
Detecting responses to treatment with fenofibrate in pedigrees.BMC Genet. 2018 Sep 17;19(Suppl 1):64. doi: 10.1186/s12863-018-0652-5. BMC Genet. 2018. PMID: 30255820 Free PMC article.
-
Comparison of novel and existing methods for detecting differentially methylated regions.BMC Genet. 2018 Sep 17;19(Suppl 1):84. doi: 10.1186/s12863-018-0637-4. BMC Genet. 2018. PMID: 30255775 Free PMC article.
-
Epigenetics, heritability and longitudinal analysis.BMC Genet. 2018 Sep 17;19(Suppl 1):77. doi: 10.1186/s12863-018-0648-1. BMC Genet. 2018. PMID: 30255778 Free PMC article.
-
A systematic review and metaanalysis of observational studies on the effects of epigenetic factors on serum triglycerides.Arch Endocrinol Metab. 2022 May 13;66(3):407-419. doi: 10.20945/2359-3997000000472. Epub 2022 May 12. Arch Endocrinol Metab. 2022. PMID: 35551677 Free PMC article.
Cited by
-
Application of novel and existing methods to identify genes with evidence of epigenetic association: results from GAW20.BMC Genet. 2018 Sep 17;19(Suppl 1):72. doi: 10.1186/s12863-018-0647-2. BMC Genet. 2018. PMID: 30255777 Free PMC article.
-
Fibrate pharmacogenomics: expanding past the genome.Pharmacogenomics. 2020 Mar;21(4):293-306. doi: 10.2217/pgs-2019-0140. Epub 2020 Mar 17. Pharmacogenomics. 2020. PMID: 32180510 Free PMC article.
References
-
- Das M, Irvin MR, Sha J, Aslibekyan S, Hidalgo B, Perry RT, Zhi D, Tiwari HK, Absher D, Ordovas JM, et al. Lipid changes due to fenofibrate treatment are not associated with changes in DNA methylation patterns in the GOLDN study. Front Genet. 2015;6:304. doi: 10.3389/fgene.2015.00304. - DOI - PMC - PubMed
-
- Das M, Sha J, Hidalgo B, Aslibekyan S, Do AN, Zhi D, Sun D, Zhang T, Li S, Chen W, et al. Association of DNA methylation at CPT1A locus with metabolic syndrome in the genetics of lipid lowering drugs and diet network (GOLDN) study. PLoS One. 2016;11(1):e0145789. doi: 10.1371/journal.pone.0145789. - DOI - PMC - PubMed
-
- Irvin MR, Zhi D, Joehanes R, Mendelson M, Aslibekyan S, Claas SA, Thibeault KS, Patel N, Day K, Jones LW, et al. Epigenome-wide association study of fasting blood lipids in the genetics of lipid-lowering drugs and diet network study. Circulation. 2014;130(7):565–572. doi: 10.1161/CIRCULATIONAHA.114.009158. - DOI - PMC - PubMed
-
- Lai CQ, Wojczynski MK, Parnell LD, Hidalgo BA, Irvin MR, Aslibekyan S, Province MA, Absher DM, Arnett DK, Ordovás JM, et al. Epigenome-wide association study of triglyceride postprandial responses to a high-fat dietary challenge. J Lipid Res. 2016;57(12):2200–2207. doi: 10.1194/jlr.M069948. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
